: The Miami CTU plans to continue to make substantial contributions to the treatment and prevention of HIV/AIDS. The CTU is structured to participate in four NIAID HIV/AIDS Clinical Research Networks to deliver high impact ground breaking research, as well as, to respond to the rapidly emerging needs of the networks. To accomplish these goals the Miami CTU intends to build upon 25 years of major contributions to the treatment and prevention of HIV infection through continuous NIAID HIV/AIDS research funding. With one of the highest incidences of HIV/AIDS in the U.S. in the Miami metropolitan area, more than 25 years of experience in the design and implementation of clinical trials places the Miami CTU in a unique position to recruit and retain diverse patient populations that are severely impacted by the epidemic. Moreover, the breadth and depth of scientific expertise allow the Miami CTU to contribute to the scientific agenda of the NIAID HIV/AIDS clinical trials networks to address the national priorities for HIV/AIDS research and the needs of the Miami metropolitan affected population. To meet these goals, we intend to establish a Miami HIV/AIDS Clinical Trials Unit (CTU) under multiple PI direction through the integration of the Miami AACTG and IMPAACT groups and the Integrated HIV prevention strategies Vaccines to prevent HIV infections clinical research network. The Miami CTU also integrates three clinical research sites (CRS) into the CTU to effectively meet the needs of the diverse patient populations and of the clinical research networks. The CTU and associated CRS are structured to foster synergy and promote economy of scale, resulting in tangible added-value to the research agenda of the NIAID clinical trials network.

Public Health Relevance

The mission and overall goal of the Miami CTU aligns with the Networks to reduce the burden of disease and infection and to develop transformative, hypothesis-driven clinical studies that test innovative approaches for the treatment and prevention of HIV infection.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RCU-A (S2))
Program Officer
Castillo, Blanca E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Miami School of Medicine
Internal Medicine/Medicine
Schools of Medicine
Coral Gables
United States
Zip Code
Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav 20:2983-2995
Singh, Kumud K; Qin, Min; Brummel, Sean S et al. (2016) Killer Cell Immunoglobulin-Like Receptor Alleles Alter HIV Disease in Children. PLoS One 11:e0151364
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Taiwo, Babafemi O; Chan, Ellen S; Fichtenbaum, Carl J et al. (2015) Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clin Infect Dis 61:1179-88
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61
Kapetanovic, Suad; Aaron, Lisa; Montepiedra, Grace et al. (2015) Effect of cytomegalovirus co-infection on normalization of selected T-cell subsets in children with perinatally acquired HIV infection treated with combination antiretroviral therapy. PLoS One 10:e0120474
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Tenorio, Allan R; Chan, Ellen S; Bosch, Ronald J et al. (2015) Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis 211:780-90
Vardhanabhuti, Saran; Ribaudo, Heather J; Landovitz, Raphael J et al. (2015) Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis 2:ofv085
Lahiri, Cecile D; Dugan, Katherine B; Xie, Xianhong et al. (2015) Oral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women. J Acquir Immune Defic Syndr 70:e63-6

Showing the most recent 10 out of 72 publications